Cargando…

337. Diagnostic Yield and Impact on Antimicrobial Management of 16s rRNA Testing on Clinical Specimens

BACKGROUND: 16s rRNA gene sequencing has an advantage over traditional bacterial culture in situations where bacteria are difficult to culture, unculturable, or have previously been exposed to antimicrobial. The study on its applicability to direct clinical specimens is still limited. We studied the...

Descripción completa

Detalles Bibliográficos
Autores principales: Eamsakulrat, Pruke, Phuphuakrat, Angsana, Santanirand, Pitak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751624/
http://dx.doi.org/10.1093/ofid/ofac492.415
_version_ 1784850517355134976
author Eamsakulrat, Pruke
Phuphuakrat, Angsana
Santanirand, Pitak
author_facet Eamsakulrat, Pruke
Phuphuakrat, Angsana
Santanirand, Pitak
author_sort Eamsakulrat, Pruke
collection PubMed
description BACKGROUND: 16s rRNA gene sequencing has an advantage over traditional bacterial culture in situations where bacteria are difficult to culture, unculturable, or have previously been exposed to antimicrobial. The study on its applicability to direct clinical specimens is still limited. We studied the value of 16s rRNA gene sequencing from direct clinical specimens on antimicrobial management. METHODS: Inpatient adults whose attending physician requested 16s rRNA gene sequencing and corresponding bacterial culture from a direct clinical specimen were prospectively included between January and December 2021. Diagnostic yield and the impact of 16s rRNA gene sequencing on antimicrobial management were investigated. RESULTS: A total of 434 specimens from 374 patients were requested. All patients had a complete follow-up and had a definitive final diagnosis. The sensitivity and specificity of 16s rRNA gene sequencing were 38.3% and 93.9%, respectively. The agreement between 16s rRNA gene sequencing and conventional culture among specimens obtained from bacterial infection cases was 83.8% (the κ coefficient 0.664, p< 0.001). Among bacterial infection cases, the proportion of 16s rRNA gene sequencing positive/culture-positive was 32.4% (82 specimens), and the proportion of sequencing positive/culture-negative was 5.9% (15 specimens). The impact on antimicrobial management occurred in 10 (2.3%) specimens, which all resulted in the continuation of antibiotics. An impact on antimicrobial management was highest in the skin and soft tissue infection, followed by bone and joint infection. In contrast, CAP/HAP/VAP was less likely to benefit from this test. Long turnaround time was the limitation of the test in this study, the median (interquartile range) was 11 (9-13) days in the 16s rRNA gene sequencing positive group, and 2 (1-4) days in the 16s rRNA gene sequencing negative group. CONCLUSION: The overall diagnostic yield of 16s rRNA gene sequencing in bacterial infection cases was fair. 16s rRNA gene sequencing was useful in selected cases, but it cannot replace traditional culture. The negative result did not exclude bacterial infection. Restrictions on test requests may improve test utilization in this setting. DISCLOSURES: All Authors: No reported disclosures.
format Online
Article
Text
id pubmed-9751624
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-97516242022-12-16 337. Diagnostic Yield and Impact on Antimicrobial Management of 16s rRNA Testing on Clinical Specimens Eamsakulrat, Pruke Phuphuakrat, Angsana Santanirand, Pitak Open Forum Infect Dis Abstracts BACKGROUND: 16s rRNA gene sequencing has an advantage over traditional bacterial culture in situations where bacteria are difficult to culture, unculturable, or have previously been exposed to antimicrobial. The study on its applicability to direct clinical specimens is still limited. We studied the value of 16s rRNA gene sequencing from direct clinical specimens on antimicrobial management. METHODS: Inpatient adults whose attending physician requested 16s rRNA gene sequencing and corresponding bacterial culture from a direct clinical specimen were prospectively included between January and December 2021. Diagnostic yield and the impact of 16s rRNA gene sequencing on antimicrobial management were investigated. RESULTS: A total of 434 specimens from 374 patients were requested. All patients had a complete follow-up and had a definitive final diagnosis. The sensitivity and specificity of 16s rRNA gene sequencing were 38.3% and 93.9%, respectively. The agreement between 16s rRNA gene sequencing and conventional culture among specimens obtained from bacterial infection cases was 83.8% (the κ coefficient 0.664, p< 0.001). Among bacterial infection cases, the proportion of 16s rRNA gene sequencing positive/culture-positive was 32.4% (82 specimens), and the proportion of sequencing positive/culture-negative was 5.9% (15 specimens). The impact on antimicrobial management occurred in 10 (2.3%) specimens, which all resulted in the continuation of antibiotics. An impact on antimicrobial management was highest in the skin and soft tissue infection, followed by bone and joint infection. In contrast, CAP/HAP/VAP was less likely to benefit from this test. Long turnaround time was the limitation of the test in this study, the median (interquartile range) was 11 (9-13) days in the 16s rRNA gene sequencing positive group, and 2 (1-4) days in the 16s rRNA gene sequencing negative group. CONCLUSION: The overall diagnostic yield of 16s rRNA gene sequencing in bacterial infection cases was fair. 16s rRNA gene sequencing was useful in selected cases, but it cannot replace traditional culture. The negative result did not exclude bacterial infection. Restrictions on test requests may improve test utilization in this setting. DISCLOSURES: All Authors: No reported disclosures. Oxford University Press 2022-12-15 /pmc/articles/PMC9751624/ http://dx.doi.org/10.1093/ofid/ofac492.415 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstracts
Eamsakulrat, Pruke
Phuphuakrat, Angsana
Santanirand, Pitak
337. Diagnostic Yield and Impact on Antimicrobial Management of 16s rRNA Testing on Clinical Specimens
title 337. Diagnostic Yield and Impact on Antimicrobial Management of 16s rRNA Testing on Clinical Specimens
title_full 337. Diagnostic Yield and Impact on Antimicrobial Management of 16s rRNA Testing on Clinical Specimens
title_fullStr 337. Diagnostic Yield and Impact on Antimicrobial Management of 16s rRNA Testing on Clinical Specimens
title_full_unstemmed 337. Diagnostic Yield and Impact on Antimicrobial Management of 16s rRNA Testing on Clinical Specimens
title_short 337. Diagnostic Yield and Impact on Antimicrobial Management of 16s rRNA Testing on Clinical Specimens
title_sort 337. diagnostic yield and impact on antimicrobial management of 16s rrna testing on clinical specimens
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751624/
http://dx.doi.org/10.1093/ofid/ofac492.415
work_keys_str_mv AT eamsakulratpruke 337diagnosticyieldandimpactonantimicrobialmanagementof16srrnatestingonclinicalspecimens
AT phuphuakratangsana 337diagnosticyieldandimpactonantimicrobialmanagementof16srrnatestingonclinicalspecimens
AT santanirandpitak 337diagnosticyieldandimpactonantimicrobialmanagementof16srrnatestingonclinicalspecimens